NASDAQ: TARA - Protara Therapeutics, Inc.

Lønnsomhet i seks måneder: +150.27%
Utbytte: 0.00%
Sektor: Healthcare

Kampanjeplan Protara Therapeutics, Inc.

Avansert tidsplan Enkel graf
Financial Markets by TradingView

Om selskapet Protara Therapeutics, Inc.

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020.

flere detaljer
The company is headquartered in New York, New York.
Legg til i sammenligningslisten
Legg til overvåkningsliste
Legg til portefølje
Legg til prisvarsel

IPO date 2014-10-22
ISIN US74365U1079
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.protaratx.com
Цена ао 4.53
Prisendring per dag: +0.8811% (4.54)
Prisendring per uke: -0.4348% (4.6)
Prisendring per måned: +30.86% (3.5)
Prisendring over 3 måneder: -16.88% (5.51)
Prisendring over seks måneder: +150.27% (1.83)
Prisendring per år: +14.21% (4.01)
Prisendring over 3 år: -18.21% (5.6)
Prisendring over 5 år: -83.63% (27.98)
Prisendring siden begynnelsen av året: -16.88% (5.51)
Alle parametere

Undervurdering

Navn Betydning Karakter
P/S 0 0
P/BV 0.6506 10
P/E 0 0
EV/EBITDA 1.01 10
Total: 5

Effektivitet

Navn Betydning Karakter
ROA, % -34.25 0
ROE, % -37.88 0
Total: 0

Utbytte

Navn Betydning Karakter
Div yield, % 0 0
DSI 0 0
Total: 0

Plikt

Navn Betydning Karakter
Debt/EBITDA -0.0912 10
Total: 8.8

Vekstimpuls

Navn Betydning Karakter
Lønnsomhet Revenue, % 0 0
Lønnsomhet Ebitda, % 43.73 6
Lønnsomhet EPS, % -53.23 0
Total: 3.4
Flere detaljer

Institusjoner Volum Dele, %
Opaleye Management Inc. 2692594 23.55
Vanguard Group Inc 427612 3.74
Boxer Capital, LLC 209227 1.83
Baker Brothers Advisors, LLC 199671 1.75
Ikarian Capital, LLC 188664 1.65
Privium Fund Management (UK) Ltd 119730 1.05
Renaissance Technologies, LLC 113300 0.99
Geode Capital Management, LLC 78518 0.69
Bridgeway Capital Management, Inc. 64000 0.56
Citadel Advisors Llc 38035 0.33

ETFDele, %Lønnsomhet for året, %Utbytte, %
iShares Micro-Cap ETF 0.00906 17.09 1.54048
0.0117.091.54



Veileder Stillingstittel Betaling Fødselsår
Mr. Jesse Shefferman Co-founder, CEO, President & Director 1.02M 1972 (53 år)
Dr. Jacqueline Zummo M.B.A., M.P.H., Ph.D. Co-Founder, Senior VP & Chief Scientific Operations Officer 694.16k 1981 (44 år)
Mr. Patrick Fabbio M.B.A. Chief Financial Officer 696.62k 1968 (57 år)
Ms. Hannah Fry VP, Principal Accounting Officer & Controller N/A 1991 (34 år)
Ms. Mary J. Grendell General Counsel & Corporate Secretary N/A
Ms. Justine O'Malley Senior Vice President of Investor Relations & Corporate Affairs

Adresse: United States, New York. NY, 345 Park Avenue South - åpne i Google maps, åpne Yandex-kart
Nettsted: https://www.protaratx.com